Breast Cancer Market

Your Catalyst to a Lucrative Business
Breast Cancer Market Size, Share, Analysis, Growth, Trends,
Competitive Strategies and Forescast to 2025 | Hexa Research
“Global breast cancer market is expected to witness a significant
growth over the forecast period”
19 February 2019, The global Breast Cancer Market is anticipated to witness a significant growth over the
forecast period on account of growing target population base across the globe, rising prevalence of the
disease, unhealthy lifestyle, exposure to radiations, and lack of physical exercises. Moreove r, increasing
efforts taken by major organizations across various regions to increase awareness levels is estimated to drive
the market. Rising investments in R&D by various government and private organizations for development of
effective drugs and treatments is also projected to play a key role in the market growth.
For instance, CytoDyn Inc., a biotech firm developing humanized CCR5 monoclonal antibodies for several
therapeutic indications, received FDA approval for its Investigation New Drug (IND) subm ission and is allowed
to start a phase 1b/2 trial for metastatic Triple-Negative Breast Cancer (TNBC). This disease subtype is one of
the leading causes of cancer deaths across the globe and it accounts for around 10 % of the overall cases. The
firm has identified several trial sites and aims to dose a few patients and expects to have initial readout
during the first quarter of 2019. Changes in the number of Circulating Tumor Cells (CTCs) will be assessed
every 21 days throughout the trial.
Browse Details of Report @
Follow Us:
Your Catalyst to a Lucrative Business
Breast cancer is detected during a screening test or after the patient notices a lump, which is the most
common physical sign. According to the World Health organization (WHO), every year, about 200,000 new
cases of breast cancer are diagnosed globally and this number is likely to increas e in future. Some of the
major types of breast cancer are ductal carcinoma in situ (DCIS), Invasive Ductal Carcinoma (IDC), and lobular
carcinoma. Invasive ductal carcinoma hold a major share in the market owing to growing prevalence of IDC,
government support, and initiatives undertaken to increase awareness among patients. Furthermore, unmet
clinical needs in treatment of IDC has compelled manufacturers to conduct rigorous R&D activities.
Chemotherapy, targeted, surgery and radiation, hormone, and biologic therapies are some of the most
popular treatments for the disease.
North America has emerged as the prominent region in the market on account of changing lifestyle, growing
prevalence of the disease, and presence of leading companies in U.S. Europe is l ikely to emerge highly
lucrative over the coming years as a result of increased healthcare expenditure and technological
developments. Countries, including Germany, France, and U.K., are some of the key revenue -generating
economies in Europe.
Asia pacific is also projected to witness a considerable growth over the next few years owing to rapidly
developing healthcare infrastructure and rising consumer disposable income. Moreover, ongoing awareness
programs about breast cancer and available treatments by governments in the emerging countries, such as
China and India are estimated to foster the growth.
Companies are adopting several business strategies, such as novel product development, technological
advancements, and M&A in order to strengthen their foothold in the industry. For example, FDA recently
approved the Investigational New Drug (IND) application for Athenex’s oral form of Eribulin. It is an
anticancer drug promoted by Eisai Company under the brand name Halaven and can effectively treat
metastatic breast cancer and liposarcoma. The company is allowed to initiate clinical trial program, which is
expected to start in the first half of 2019. Other targeted therapies introduced to treat breast cancer include
Perjeta (pertuzumab) and Kadcyla (T-DM1), which is a human antibody-drug conjugate. Leading companies
operating in the global breast cancer market include Pfizer, Inc.; Novartis AG; Apthera, Inc.; BioNumerik
Pharmaceuticals, Inc.; Eli Lilly and Company; and Oncothyreon, Inc.
Browse Related Category Market Reports @
Follow Us:
Your Catalyst to a Lucrative Business
About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research
and consulting services to a host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients obtain clarity about their business
environment and enable them to undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: [email protected]
Follow Us:

The global breast cancer market is anticipated to witness a significant growth over the forecast period.